News

10x Genomics price target lowered to $12 from $16 at BofA
BofA analyst Michael Ryskin lowered the firm’s price target on 10x Genomics (TXG) to $12 from $16 and keeps a Neutral rating on the shares.
StockStory.org on MSN10d
Q4 Earnings Outperformers: 10x Genomics (NASDAQ:TXG) And The Rest Of The Life Sciences Tools & Services Stocks
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the life sciences tools & ...
Seeking Alpha4d
10x Genomics to Report First Quarter 2025 Financial Results on May 8, 2025
PLEASANTON, Calif., April 14, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced it will report financial results for the first quarter ...
Forbes1d
10x Genomics
10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell ...
Seeking Alpha3d
TXG 10x Genomics, Inc.
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the Americas, Europe, the Middle East ...
Immune Repertoire Sequencing Market worth US$560.5 million by 2030 with 9.6% CAGR | MarketsandMarkets
The global Immune Repertoire Sequencing Market, valued at US$344.2 million in 2024, is forecasted to grow at a robust CAGR of 9.6%, reaching ...
Immune Repertoire Sequencing Market worth US$560.5 million by 2030 with 9.6% CAGR | MarketsandMarkets™
The global Immune Repertoire Sequencing Market, valued at US$344.2 million in 2024, is forecasted to grow at a robust CAGR of 9.6%, ...
StockStory.org on MSN9d
PacBio (PACB) and Hims & Hers Health (HIMS), 10x Genomics (TXG), Moderna (MRNA) Shares Are Soaring, What You Need To Know
What Happened? A number of stocks jumped in the afternoon session after markets rallied sharply on news that President Trump ...